STRATENITY · INDUSTRY ONE-PAGER · PANDEMIC PREPAREDNESS
CONFIDENTIAL · JULY 2026
Pandemic Preparedness
Industry Outlook · Global Health Security · 2026
Scan Type
Industry Snapshot
Structured, repeatable read of sector economics, signals, gaps, and engagement pathways.
Preparedness Gap
~$30B / yr
Estimated annual investment to prepare
vs. trillions in avoided pandemic cost
STRATENITY READ · Pandemic and public health preparedness is a structurally underfunded, high-stakes sector where the cost of readiness is a rounding error against the cost of failure. COVID-19 inflicted economic losses estimated in the trillions of dollars, yet preparedness financing remains cyclical: attention and funding surge during a crisis and recede once the emergency fades, leaving surveillance, stockpiles, and countermeasure platforms chronically under-resourced. The core tension is durable: threats are accelerating from zoonotic spillover, antimicrobial resistance, and a warming climate, while the political will to sustain financing between emergencies is fragile. Organizations and governments that win will treat rapid-countermeasure platforms, genomic and wastewater surveillance, supply resilience, and cross-border governance as one connected preparedness system rather than isolated programs rebuilt after each shock. The advantage goes to those who lock in sustained financing and a 100-day countermeasure capability before the next spillover, not after it.
$14T+
COVID Economic Cost
Cumulative global output loss estimated in the trillions.
100d
Countermeasure Mission
Target to field safe vaccines and therapeutics after a new threat.
~$30B
Annual Preparedness Need
Estimated yearly investment to prepare across systems.
<1%
of Response Cost
Prevention spend is a fraction of what a pandemic costs.
3-4x
Zoonotic Spillover Risk
Emergence frequency rising with land use and climate change.
~50%
Funding Decay
Preparedness budgets erode sharply once an emergency recedes.
01 Industry Profile
Sub-sectorsSurveillance, Countermeasures, Stockpiles, Governance
Preparedness need~$30B / yr estimated global investment
Cost of failureTrillions in output loss (COVID-19)
Funding mixNational budgets, multilaterals, philanthropy, industry
CoordinationWHO IHR, national frameworks, CEPI, GHSA
02 Cycle Drivers
1
Funding cyclicality and complacency. Preparedness budgets surge in a crisis and erode once the emergency fades, leaving systems under-resourced.
2
Rapid-platform countermeasures. mRNA and other platforms plus the 100-day mission move vaccine and therapeutic timelines from years to months.
3
Surveillance and early warning. Genomic sequencing and wastewater monitoring enable earlier detection of novel and variant threats.
4
Zoonotic and AMR pressure. Spillover risk, one-health gaps, and antimicrobial resistance raise the baseline threat level.
Major Players
WHO
US CDC
BARDA
CEPI
Coalition for Epidemic Preparedness
Moderna / Pfizer platforms
Wellcome
03 Industry Signals
Preparedness funding cyclicality and complacency
Financing spikes during outbreaks and decays afterward; sustaining investment between emergencies is the central strategic problem.
Rapid-platform vaccines and the 100-day mission
mRNA and modular platforms plus CEPI's 100-day mission compress countermeasure timelines, but require standing capacity and financing.
Surveillance, genomic sequencing, and wastewater
Genomic and wastewater monitoring provide earlier signals, yet coverage and data integration remain uneven across regions.
Supply and stockpile resilience
PPE, countermeasures, and inputs face concentration and shortage risk; stockpiles decay and single-source dependencies persist.
One-health, AMR, and zoonotic risk
Spillover at the human-animal-environment interface and rising resistance broaden the threat surface and demand cross-sector coordination.
05 Sector Recommendations
NowLock in sustained, multi-year preparedness financing insulated from the crisis-and-complacency cycle, with clear governance and accountability.
30-60dStand up standing rapid-countermeasure capacity aligned to the 100-day mission, with pre-negotiated platforms, manufacturing, and trial readiness.
60-90dIntegrate genomic, wastewater, and clinical surveillance into one early-warning platform with shared data flows and cross-border reporting.
04 Industry Gap Analysis
G1
Sustained financing and complacency. Funding follows crises then erodes; preparedness lacks durable, ring-fenced investment between emergencies.
G2
Surveillance and early warning. Genomic and wastewater coverage is patchy; signals are slow to detect, integrate, and act on across borders.
G3
Countermeasure platforms and speed. 100-day capability needs standing platforms, manufacturing, and trial infrastructure kept warm between events.
G4
Supply and stockpile resilience. PPE, countermeasures, and inputs face single-source risk; stockpiles expire and rotation is under-managed.
G5
Coordination and governance. Fragmented mandates and weak cross-border governance slow response; IHR and accord commitments outpace execution.
G6
Workforce and health systems. Surge capacity, public health workforce, and one-health capability are thin and slow to mobilize.
Stratenity Signal Profile
Threat level
High / Rising
Funding stability
Cyclical / Weak
Regulatory
IHR / EUA / Accord
Platform readiness
Advancing
Primary Domain
Preparedness Financing & Countermeasure Readiness
Recommended Module
VelorStrategy · Execution Workspace
Suggested assets: Preparedness Financing Model · 100-Day Countermeasure Playbook · Surveillance Integration Kit
Data confidence: High (public sources)
Last reviewed: July 2026
06 Strategic Engagement Opportunities
| Engagement Track | Strategic Thesis | $ Range |
|---|
| Preparedness Financing / Strategy | Design durable, ring-fenced financing and a national preparedness strategy insulated from the crisis-and-complacency cycle. | $300K-$2M |
| Surveillance / Early-Warning Platform | Integrate genomic, wastewater, and clinical signals into one early-warning platform with cross-border data flows. | $250K-$1.5M |
| Rapid-Countermeasure Readiness | Stand up 100-day platform, manufacturing, and trial capacity kept warm between events for vaccines and therapeutics. | $350K-$2.2M |
| Supply / Stockpile Resilience | Re-engineer PPE and countermeasure stockpiles, rotation, and multi-source supply to remove single-point failure. | $220K-$1.2M |
| Coordination / Governance | Build cross-border governance, IHR and accord alignment, and clear response mandates and accountability. | $180K-$900K |
| Health-System Surge Capacity | Design surge staffing, public health workforce, and care-model plans to mobilize capacity fast in an emergency. | $160K-$850K |
| One-Health / AMR | Stand up one-health surveillance and antimicrobial-resistance programs at the human-animal-environment interface. | $150K-$800K |
Total Addressable Engagement Value
$1.6M - $9.5M
across a 12-24 month engagement horizon
·Industry Outlook
Repeatable, versioned sector read covering economics, signals, gaps, and cycle drivers.
·Competitor Scans
Structured profiles of agencies, funders, and platform players with positioning and moves.
·Market Entry Scan
Entry, expansion, and partnership analysis scoped to a target program or geography.
·Bespoke / Regulatory
Advisory on IHR, pandemic accord, and EUA exposure plus governed preparedness deployment paths.
We can build this same industry view on any sector your clients pursue.
One repeatable, governed format across every market you advise, from healthcare to fintech to energy.
REQUEST A SECTOR SCAN